- Home
- XRTX vs QNRX Comparison
XRTX vs QNRX Comparison
Compare XRTX & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XRTX
- QNRX
- Stock Information
- Founded
- XRTX 2011
- QNRX 2018
- Country
- XRTX Canada
- QNRX United States
- Employees
- XRTX N/A
- QNRX N/A
- Industry
- XRTX Pharmaceuticals and Biotechnology
- QNRX Medical/Dental Instruments
- Sector
- XRTX Health Care
- QNRX Health Care
- Exchange
- XRTX Nasdaq
- QNRX Nasdaq
- Market Cap
- XRTX 3.0M
- QNRX 2.5M
- IPO Year
- XRTX N/A
- QNRX N/A
- Fundamental
- Price
- XRTX $0.96
- QNRX $0.29
- Analyst Decision
- XRTX
- QNRX
- Analyst Count
- XRTX 0
- QNRX 0
- Target Price
- XRTX N/A
- QNRX N/A
- AVG Volume (30 Days)
- XRTX 16.6K
- QNRX 10.6M
- Earning Date
- XRTX 05-16-2025
- QNRX 03-13-2025
- Dividend Yield
- XRTX N/A
- QNRX N/A
- EPS Growth
- XRTX N/A
- QNRX N/A
- EPS
- XRTX N/A
- QNRX N/A
- Revenue
- XRTX N/A
- QNRX N/A
- Revenue This Year
- XRTX N/A
- QNRX N/A
- Revenue Next Year
- XRTX N/A
- QNRX N/A
- P/E Ratio
- XRTX N/A
- QNRX N/A
- Revenue Growth
- XRTX N/A
- QNRX N/A
- 52 Week Low
- XRTX $0.82
- QNRX $0.21
- 52 Week High
- XRTX $3.92
- QNRX $1.57
- Technical
- Relative Strength Index (RSI)
- XRTX 49.57
- QNRX 49.51
- Support Level
- XRTX $0.90
- QNRX $0.21
- Resistance Level
- XRTX $1.10
- QNRX $0.32
- Average True Range (ATR)
- XRTX 0.08
- QNRX 0.03
- MACD
- XRTX -0.00
- QNRX -0.00
- Stochastic Oscillator
- XRTX 38.60
- QNRX 38.70
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.